Aspen Pharmacare Hldgs (APNHF) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good to see you all here today. And welcome to Aspen's full year financial results for the 2024 period. In today's program, we're going to have Stephen, who's going to start us off with the performance overview. Sean will then follow with the financial highlights and review. Stephen will then return, and he's going to give us the strategic review and some outlook. And then we'll move on to questions and answers. The attendees that are joining us online are requested to put their questions in the left-hand side of the screen, and that question box is already open. For our attendees in the room today, we'll be using a roving mic. Thank you all. Over to you, Stephen. Good morning everyone, lovely to be here and thank you for your attendance and for, I believe there are many, many more online, so welcome to all that are listening. I think if we reflect on where we are and where we're going to, this second half was a really important half for Aspen. We flagged it over a year ago as being a critical inflection point for Aspen and indeed it was. We had some very, very important deliverables. know after the last seven to eight years we've we've had pretty much uh you know we building this and this might happen and if we operationalize successfully or take transfer then this will happen For the last few years, we've been flagging, for example, the VBP risks in China. So there were lots of risks. So it was always, this is where we're going, but these are potential threats to the business. I mean, to quantify these type of things, the commercial farmer business had a couple of billion rand, over a billion rand in gross margin at risk between China and Russia. And in fact, China was even worse. So that's a challenge we had to choose. We had to work out what we deal with. It's on...